CSPC PHARMA (01093): SYH2085 Tablets Receive Clinical Trial Approval in China

Stock News12-19

CSPC PHARMA (01093) announced that its self-developed SYH2085 tablets have obtained clinical trial approval from China's National Medical Products Administration (NMPA). The product is a Class 1 innovative chemical drug designed to inhibit the PA endonuclease activity of influenza virus RNA polymerase.

This oral small-molecule drug candidate has been approved for clinical trials targeting uncomplicated influenza A and B in adults and adolescents aged 12 and above. Preclinical studies demonstrate that SYH2085 exhibits broad-spectrum and potent antiviral effects against both influenza A and B viruses, effectively reducing viral load and flu-like symptoms in animal models while maintaining favorable pharmacokinetic and safety profiles.

With significant clinical development potential, SYH2085 is expected to become an effective influenza treatment, further strengthening CSPC PHARMA's anti-infective therapeutic pipeline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment